24 August 2018: vol 19 no 14: AIDS 2018 – next reports…
24 August 2018. Related: Editorial.
2018
22nd International AIDS Conference (AIDS 2018) – second reports
24 August 2018. Related: Conference reports.
Namibia close to achieving 90-90-90 targets
24 August 2018. Related: Conference reports, Treatment access.
Dolutegravir monotherapy: still no longer recommended in either research or clinical practice
24 August 2018. Related: Conference reports, Treatment strategies.
Changing comorbidities in HIV positive people older than 60 at London clinic
24 August 2018. Related: Conference reports, Coinfections and complications.
High acceptability of annual digital (finger) exam for early detection of anal cancer in gay men >35 years old
24 August 2018. Related: Conference reports, Coinfections and complications, Cancer and HIV.
High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination
24 August 2018. Related: Conference reports, Cancer and HIV, HIV prevention and transmission.
HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands
24 August 2018. Related: Conference reports, Hepatitis coinfection.
FDA-approved compounds that might selectively reverse HIV latency
24 August 2018. Related: Conference reports, Cure-related research.
Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans
24 August 2018. Related: Conference reports, Cure-related research.
Janssen HIV vaccine: update from APPROACH and largescale efficacy study
24 August 2018. Related: Conference reports, HIV prevention and transmission, Cure-related research.
Viral load testing in Latin America and the Caribbean
24 August 2018. Related: Conference reports, Treatment access, Diagnostics.
Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire
24 August 2018. Related: Conference reports, Treatment access, Guidelines.
Resolving a diagnosis for people with persistently indeterminate HIV test results
24 August 2018. Related: Conference reports, Diagnostics, HIV prevention and transmission.
10th International Workshop on HIV Paediatrics – second reports
24 August 2018. Related: Conference reports.
Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy
24 August 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections
24 August 2018. Related: Antiretrovirals.
Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates
24 August 2018. Related: Antiretrovirals, PK and drug interactions.
More than ten people a day died from drug-related deaths in England and Wales last year:
24 August 2018. Related: Other news.
We learn, we think, we change: Martin Fisher Foundation and Stiggy launch campaign to end stigma
24 August 2018. Related: On the web.
24 August 2018: vol 19 no 14
24 August 2018. Related: PDFs.
03 August 2018: vol 19 no 13: AIDS 2018 – first reports
3 August 2018. Related: Editorial.
22nd International AIDS Conference (AIDS 2018) – first reports
3 August 2018. Related: Conference reports.
Caution on press conference news from AIDS 2018
3 August 2018. Related: Conference reports.
Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV
3 August 2018. Related: Conference reports, HIV prevention and transmission.
DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study
3 August 2018. Related: Conference reports, Antiretrovirals.
Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study
3 August 2018. Related: Conference reports, Treatment strategies.
Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil
3 August 2018. Related: Conference reports, Antiretrovirals, Treatment access.
WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)
3 August 2018. Related: Conference reports, Women's health, Pregnancy, Guidelines.
No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)
3 August 2018. Related: Conference reports, Pregnancy.
Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1
3 August 2018. Related: Conference reports, Pregnancy.
First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough
3 August 2018. Related: Conference reports, Cure-related research.
Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen
3 August 2018. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians
3 August 2018. Related: Conference reports, HIV prevention and transmission.
AIDS 2018 online: links to selected webcasts
3 August 2018. Related: Conference reports.
10th International Workshop on HIV Paediatrics – first reports
3 August 2018. Related: Conference reports, Paediatric care.
Preconception safety signal with dolutegravir: data from the Tsepamo study
3 August 2018. Related: Conference reports, Pregnancy.
03 August 2018: vol 19 no 13
3 August 2018. Related: PDFs.
Fit for purpose: Antiretroviral treatment optimisation July 2018
23 July 2018. Related: Special reports, Supplements, Pipeline report, Fit for purpose, Antiretrovirals.
Fit for purpose 2018 – PDF
23 July 2018. Related: Special reports, Supplements, Fit for purpose, PDFs.
What to watch: HIV cure-related research at AIDS 2018
20 July 2018. Related: Conference reports, Cure-related research.
HIV pipeline 2018: full version
11 July 2018. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
11 July 2018: vol 19 no 12: DTG and preconception – special report
11 July 2018. Related: Editorial.
Dolutegravir preconception signal: time is up for shoddy surveillance
11 July 2018. Related: Special reports, Pregnancy.
AIDS 2018: Programme online and late-breaker highlights announced three weeks before the conference
11 July 2018. Related: Conference reports.
Bictegravir/FTC/TAF (Biktarvy) approved in Europe
11 July 2018. Related: Antiretrovirals.
Dolutegravir: need to consider all pros and cons before switching in pregnancy
11 July 2018. Related: Women's health, Pregnancy.
Why U=U does not apply to breastfeeding
11 July 2018. Related: Pregnancy, HIV prevention and transmission.
11 July 2018: vol 19 no 12
11 July 2018. Related: PDFs.
29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports
29 June 2018. Related: Editorial.
New contraindication against using darunavir/cobicistat during pregnancy
29 June 2018. Related: Treatment alerts, Antiretrovirals.
Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
29 June 2018. Related: Treatment alerts, Pregnancy.
19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore
29 June 2018. Related: Conference reports.
Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole
29 June 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin
29 June 2018. Related: Conference reports, PK and drug interactions.
Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort
29 June 2018. Related: Conference reports, PK and drug interactions, Side effects.
China approves albuvirtide: a once-weekly injectable entry inhibitor
29 June 2018. Related: Antiretrovirals.
Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance
29 June 2018. Related: Antiretrovirals.
New FDA guidance for developing PrEP drugs
29 June 2018. Related: HIV prevention and transmission.
UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people
29 June 2018. Related: HIV prevention and transmission.
RITA: issue on lung health
29 June 2018. Related: Coinfections and complications, On the web.